LifeTech ScientificFRA:81X -0.71%96 Net Margin % is 13.38% as of Dec. 2025, which is 48% below its 10-year median of 25.70. GuruFocus rates FRA:81X with a GF Score™ of 96/100 and a GF Value™ of €0.21. The stock has 4 warning signs investors should review. Among 817 Medical Devices & Instruments companies, LifeTech Scientific ranks better than 75.28% on this metric.
The historical rank and industry rank for LifeTech Scientific's Net Margin % or its related term are showing as below:
FRA:81X'
s Net Margin % Range Over the Past 10 Years
Min: 10.79 Med: 25.7 Max: 41.28
Current: 10.81
FRA:81X's Net Margin % is ranked better than 75.28% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.09
vs FRA:81X: 10.81
LifeTech Scientific (FRA:81X) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
LifeTech Scientific Net Margin % Related Terms
LifeTech Scientific Net Margin % Historical Data
* Premium members only.
The historical data trend for LifeTech Scientific's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, LifeTech Scientific's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LifeTech Scientific Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LifeTech Scientific's Net Margin % distribution charts can be found below:
* The bar in red indicates where LifeTech Scientific's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LifeTech Scientific (FRA:81X) has a Net Margin % of 13.38% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on LifeTech Scientific and its competitors. This is 48% below median its historical median of 25.70. Over the past decade, LifeTech Scientific's Net Margin % has ranged from 10.79 to 41.28. According to the industry distribution chart, LifeTech Scientific ranks #202 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 24.7%.
Is LifeTech Scientific's Net Margin % too high?
LifeTech Scientific's current Net Margin % of 13.38% is 48% below median its 10-year median of 25.70. Over the past 10 years, this metric has ranged from a low of 10.79 to a high of 41.28. The Medical Devices & Instruments industry median Net Margin % is 2.09. LifeTech Scientific's value of 13.38% is 540.2% above this industry median. Based on the distribution chart, LifeTech Scientific ranks #202 out of 817 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, LifeTech Scientific has a GF Score™ of 96/100, reflecting its overall financial health beyond just this single metric.
How does LifeTech Scientific's Net Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, LifeTech Scientific ranks #202 out of 817 companies for Net Margin %. This places LifeTech Scientific in the top 25% of its industry — outperforming the majority of peers. The industry median Net Margin % is 2.09. LifeTech Scientific's value of 13.38% is 540.2% above this benchmark. Historically, LifeTech Scientific's own Net Margin % has ranged from 10.79 to 41.28 over the past decade. While the company's 10-year median is 25.70 vs. the industry median of 2.09, LifeTech Scientific has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.09, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LifeTech Scientific's current Net Margin % of 13.38% is 540.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on LifeTech Scientific and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LifeTech Scientific's current Net Margin % is 13.38%, which is 48% below median its own 10-year median of 25.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LifeTech Scientific stock overvalued right now?
LifeTech Scientific (FRA:81X) has a current Net Margin % of 13.38%. The stock's GF Value™ is €0.21, compared to a current price of €0.14 — trading 33.3% below its estimated fair value. The current Net Margin % is 13.38%, which is 48% below median its 10-year median of 25.70 and 540.2% above the Medical Devices & Instruments industry median of 2.09. LifeTech Scientific's overall GF Score™ is 96/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For LifeTech Scientific (FRA:81X), the current Net Margin % is 13.38% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LifeTech Scientific (FRA:81X) Overvalued in 2026?
Based on GuruFocus' analysis, LifeTech Scientific stock appears to be undervalued.
The current stock price of €0.14 is trading 33.3% below its estimated GF Value™ of €0.21.
Key valuation signals for FRA:81X:
Net Margin %: 13.38% (48% below median its 10-year median of 25.70)
GF Value™: €0.21 vs. price of €0.14 (33.3% below fair value)
Industry Position: 540.2% above the Medical Devices & Instruments median (#202 of 817)
No single metric tells the full story. See the FRA:81X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LifeTech Scientific Corp develops and manufactures also responsible for marketing of minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The firm operates in three areas: the Structural heart diseases business, the Peripheral vascular diseases business, and the Cardiac pacing and electrophysiology business. It generates maximum revenue from the Peripheral Vascular Diseases business segment. Geographically, it derives a majority of its revenue from Mainland China, and it also has its presence in Europe, Asia, excluding mainland China and India, India, South America, Africa, and Others.
96GF Score
Get the complete analysis for FRA:81X
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:81X has been successfully added to your 
